Abstract
The classic description of primary hyperparathyroidism (PHPT) is as a disease of kidney stones and bones. However, the clinical manifestation of osteitis fibrosa cystica with severe bone changes is rare in modern medicine. We present a clinical case of a 30-year-old man with severe bone deformities of the long bones, scoliosis, brown tumors and severe osteoporosis. At the time of the diagnosis, he has the classic biochemical and hormonal picture of primary hyperparathyroidism: severe hypercalcemia, hypophosphatemia, and significantly elevated parathyroid hormone values. The changes are temporarily affected after surgical treatment of the parathyroid adenoma. After a four-year loss to follow-up, the patient presented with worsening symptoms and hypercalcemia, possibly due to incomplete tumor removal. The bone changes are debilitating and imply incomplete reverse development, considering their severity and duration. Comparison is made with other similar cases in the literature.
References
- Recklinghausen, F. Die fibröse oder deformirende Ostitis, die Osteomalacie und die osteoplastische Carcinose in ihren ge-genseitigen Beziehungen, 1891.
- Misiorowski W, Bilezikian JP. Osteitis Fibrosa Cystica. JBMR Plus 2020; 4, e10403.
- Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperpara-thyroidism. The Lancet 2018; 391, 168–178.
- Minisola S et al. Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism. J Bone Miner Res 2022; 37, 2315–2329.
- Abood A, Vestergaard P. Increasing incidence of primary hy-perparathyroidism in Denmark. Dan Med J 2013; 60, A4567.
- Soto-Pedre E, Newey PJ, Leese GP. Stable Incidence and Increasing Prevalence of Primary Hyperparathyroidism in a Population-based Study in Scotland. The Journal of Clinical Endocrinology & Metabolism 2023; 108, e1117–e1124.
- Schini M et al. Normocalcemic Hyperparathyroidism: Study of its Prevalence and Natural History. The Journal of Clinical Endocrinology & Metabolism 2020; 105, e1171–e1186.
- Ma YL et al. Catabolic Effects of Continuous Human PTH (1–38) in Vivo Is Associated with Sustained Stim-ulation of RANKL and Inhibition of Osteoprotegerin and Gene-Associated Bone Formation. Endocrinology 2001; 142, 4047–4054.
- Osagie-Clouard L et al. Parathyroid hormone 1-34 and skel-etal anabolic action: The use of parathyroid hormone in bone formation. Bone & Joint Research 2017; 6, 14–21.
- Nakchbandi IA, Lang R, Kinder B, Insogna KL. The Role of the Receptor Activator of Nuclear Factor-κB Ligand/Osteo-protegerin Cytokine System in Primary Hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism 2008; 93, 967–973.
- EL-Sobky TA, Ahmad KA, Samir S, El Mikkawy DME. Pri-mary hyperparathyroidism in a child: The musculoskeletal manifestations of a late presenting rare endocrinopathy. The Egyptian Journal of Radiology and Nuclear Medicine 2016, 47, 1613–1616.
- Tuli G et al. Primary Hyperparathyroidism (PHPT) in Chil-dren: Two Case Reports and Review of the Literature. Case Reports in Endocrinology 2021, 1–6.
- Bilezikian JP, Silverberg SJ, Shane E et al. Characterization and evaluation of asymptomatic primary hyperparathyroid-ism. J Bone Miner Res 6 Suppl 2, S85-89; discussion 1991; S121-124.
- De Crea C et al. Are brown tumours a forgotten disease in developed countries? Acta Otorhinolaryngol Ital 2012; 32, 410–415.
- Parnell KE, Oltmann SC. The Surgical Management of Pri-mary Hyperparathyroidism: An Updated Review. Int. J. Endo. Oncol. 2018; 5, IJE07.
- Agarwal G et al. Recovery pattern of patients with osteitis fi brosa cystica in primary hyperparathyroidism after success-ful parathyroidectomy. Surgery 2002; 132, 1075–1085.
- Westerdahl J. Risk Factors for Postoperative Hypocalcemia After Surgery for Primary Hyperparathyroidism. Arch Surg 2000, 135, 142
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.